CD274 and head and neck squamous cell carcinoma: However, the results of the Phase III JAVELIN Head and Neck 100 trial evaluating avelumab (PD-L1 inhibitor) plus CRT followed by avelumab maintenance versus CRT in patients with locally advanced HNSCC did not show any survival benefits (PFS stratified HR 1.21, 95% CI 0.93–1.57; stratified p-value 0.92 and OS stratified HR 1.31, 95% CI 0.93–1.85; stratified p-value 0.94; ClinicalTrials.gov Identifier: NCT02952586) [70].